KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Long-term efficacy and immune response of CoronaVac in Brazilian health care workers: Insights from PROFISCOV unblinded trial.

Maria da Graça Salomão, Caroline de Almeida Leitão Curimbaba, Patrícia Emília Braga, João Italo Dias França, Elizabeth Gonzalez Patino, Fernanda Castro Boulos, José Alfredo de Sousa Moreira, PROFISCOV Study Group

Vaccine 62 127527

PMID40714527
PMCID-
DOI10.1016/j.vaccine.2025.127527
发表日期2025-07-27
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

Covid-19 remains a global threat due to vaccine-waning immune responses, and the need to update to emerging variants. This study presents the post-unblinding analysis of the PROFISCOV trial (NCT04456595), a double-blind, randomized, placebo-controlled phase 3, among adult healthcare workers (HCWs≥18y). A cohort (N = 12,688) was randomized to receive a two-dose regimen of the inactivated COVID-19 vaccine (CoronaVac) or placebo (1:1), 14 days apart. ANVISA granted emergency use authorization for CoronaVac in January 2021, prompting the study's unblinding. Outcomes included incidence of symptomatic confirmed COVID-19 cases (RT-PCR), immune response over one year, and effects of boosters among the vaccinees. Population (N = 1554) exhibited a reduction in confirmed cases from November 2021, peaking from December 2021 to February 2022, when the Omicron wave prevailed. Mean IgG-RBD titres increased from baseline to the 52nd week. IgG-N titres peaked in the 13th week and declined. The homologous booster enhanced significantly the immune response compared to the heterologous one (Pfizer).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。